To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2013 News Releases

About RSS

Participation in "Global Health Innovative Technology Fund (GHIT Fund)"

April 8, 2013

TOKYO, April 8, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that Astellas participated in the Global Health Innovative Technology Fund (GHIT Fund), the first public-private partnership of its kind in Japan. The GHIT Fund has been established to advance the research and development of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world which Astellas has supported its purpose.


The GHIT Fund is supported by the Government of Japan, five Japanese pharmaceutical companies including Astellas, and the Bill & Melinda Gates Foundation. The GHIT Fund aims to reinforce Japan’s contribution to global health by developing new health technologies for HIV/AIDS, malaria, tuberculosis and Neglected Tropical Diseases (NTDs) through utilizing the highly developed science and technology capacity found at the country’s pharmaceutical companies, universities and research institutions. Also, the GHIT Fund will facilitate and fund global R&D of new health technologies through partnership creation, providing grants for promising research. The fund will help bridge the gap between basic research and clinical studies accelerating the development of unprecedented medicines, vaccines and diagnostics to eliminate infectious diseases in the developing world.


Astellas is committed to accelerate the discovery of new drugs for patients suffering from NTDs in the world, through our commitment on collaborative drug-discovery research projects especially for new anti-protozoan or anti-dengue virus drugs, which have been advanced with multiple leading research institutes in Japan. Astellas also contributes to the development of the first-ever pediatric formulation of praziquantel. Astellas believes that the participation in GHIT Fund is as part of such efforts. Astellas will continue to contribute to improve global public health problems by promoting further drug-discovery for patients infected with and suffering from NTDs.



Printer-friendly version

Main Text end
Local Navigation
Local Navigation end
Related Links